3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Breast Neoplasms
1
Interventions
Pemetrexed
9
Carboplatin
7
pembrolizumab
6
Cisplatin
6
130-nm albumin-bound paclitaxel
6
Paclitaxel
5
Nivolumab
5
Gemcitabine
5
palbociclib
4
napabucasin
4
durvalumab
4
Fulvestrant
4
Bevacizumab
4
ribociclib
3
osimertinib
3
abemaciclib
3
Mitomycin
3
Irinotecan
3
Fluorouracil
3
Drug Therapy
3
Anastrozole
3
Albumin-Bound Paclitaxel
3
selpercatinib
2
pralsetinib
2
patritumab
2
ficlatuzumab
2
exemestane
2
atezolizumab
2
Watchful Waiting
2
Trabectedin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms by Site
×
Acetic Acid
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled